Table 1.
(a) Preoperative Characteristics. Total number of patients in each study listed as N. Median age (IQR) was 67 years old and 69 years old in RS-RARP and S-RARP, respectively. Median Preoperative weighted PSA was 4.12 ng/mL in RS-RARP and 4.65 ng/mL in S-RARP. Preoperative Gleason grading is shown with total numbers of the study participants with GG1 22%, GG2 23%, GG3 18%, GG4 20%, and GG5 13% in RS-RARP, and 8%, 28%, 23%, 15%, AND 15% in S-RARP. (b) Patterns of local treatment prior to RP presented with individual studies and total N. In RS-RARP, 21% underwent brachytherapy, 52% underwent EBRT, 1% had SBRT, 20% underwent HIFU, 2% had cryoablation, and 4% with other treatment. In S-RARP, 27% underwent Brachy-therapy, 49% had EBRT, 7% had SBRT, 2% with HIFU, 13% with cryoablation, and 2% with other treatment. There were no significant differences in treatment type in any study.
| (a): Preoperative Characteristics | |||||
|---|---|---|---|---|---|
| Study | SRS | SS | p–Value | ||
| N | Schuetz et al. [20] | 21 | 7 | ||
| Madi et al. [19] | 20 | 6 | |||
| Kowalczyk et al. [21] | 40 | 32 | |||
| Total | 81 | 45 | |||
| Age (Median [IQR]) | Schuetz et al. [20] | 67 (65–71) | 69 (61–70) | 0.4 | |
| Madi et al. [19] | 70 (64–73) | 65 (57–68) | 0.65 | ||
| Kowalczyk et al. [21] | 68 (63–70) | 66 (60–70) | 0.804 | ||
| Median weighted | 68.2345679 | 66.3333333 | |||
| Median Pre–Op PSA (IQR) | Schuetz et al. [20] | 2.5 (1.6–4.4) | 5.6 (1.8–6.1) | 0.05 | |
| Madi et al. [19] | 5.0 (3.2–6.2) | 6.5 (3.9–9.4) | 0.18 | ||
| Kowalczyk et al. [21] | 4.6 (2.6–8.3) | 4.1 (2.7–6.6) | 0.876 | ||
| Median weighted | 4.12345679 | 4.65333333 | |||
| GG1 | Schuetz et al. [20] | ||||
| Madi et al. [19] | 4/20 (25%) | 1/7 (14%) | |||
| Kowalczyk et al. [21] | 9/40 (23%) | 2/32 (6%) | |||
| Total | 13/60 (22%) | 3/39 (8%) | |||
| GG2 | Schuetz et al. [20] | ||||
| Madi et al. [19] | 5/20 (25%) | 3/7 (43%) | |||
| Kowalczyk et al. [21] | 9/40 (23%) | 8/32 (25%) | |||
| Total | 14/60 (23%) | 11/39 (28%) | |||
| Pre–Op Gleason Grade | GG3 | Schuetz et al. [20] | |||
| Madi et al. [19] | 3/20 (15%) | 1/7 (14%) | |||
| Kowalczyk et al. [21] | 8/40 (20%) | 8/32 (25%) | |||
| Total | 11/60 (18%) | 9/39 (23%) | |||
| GG4 | Schuetz et al. [20] | ||||
| Madi et al. [19] | 7/20 (35%) | 1/7 (14%) | |||
| Kowalczyk et al. [21] | 5/40 (13%) | 5/32 (16%) | |||
| Total | 12/60 (20%) | 6/39 (15%) | |||
| GG5 | Schuetz et al. [20] | ||||
| Madi et al. [19] | 1/20 (5%) | 0/7 (0%) | |||
| Kowalczyk et al. [21] | 7/40 (18%) | 6/32 (19%) | |||
| Total | 8/60 (13%) | 6/39 (15%) | |||
| Total | Schuetz et al. [20] | ||||
| Madi et al. [19] | 0.71 | ||||
| Kowalczyk et al. [21] | 0.487 | ||||
| (b): Preoperative Characteristics | |||||
| Study | SRS | SS | p –Value | ||
| Brachy | Schuetz et al. [20] | 2/21 (10%) | 2/7 (29%) | ||
| Madi et al. [19] | 3/20 (15%) | 1/6 (18%) | |||
| Kowalczyk et al. [21] | 12/40 (30%) | 9/32 (28%) | |||
| Total | 17/81 (21%) | 12/45 (27%) | |||
| EBRT | Schuetz et al. [20] | 6/21 (29%) | 3/7 (43%) | ||
| Madi et al. [19] | 15/20 (75%) | 3/6 (50%) | |||
| Kowalczyk et al. [21] | 21/40 (53%) | 16/32 (50%) | |||
| Total | 42/81 (52%) | 22/45 (49%) | |||
| SBRT | Schuetz et al. [20] | ||||
| Madi et al. [19] | 1/20 (5%) | 1/6 (18%) | |||
| Kowalczyk et al. [21] | 0/40 (0%) | 2/32 (6%) | |||
| Total | 1/81 (1%) | 3/45 (7%) | |||
| Local Treatment | HIFU | Schuetz et al. [20] | 9/21 (43%) | 1/7 (14%) | |
| Madi et al. [19] | 0/20 (0%) | 0/6 (0%) | |||
| Kowalczyk et al. [21] | 7/40 (18%) | 0/32 (0%) | |||
| Total | 16/81 (20%) | 1/45 (2%) | |||
| Cryoablation | Schuetz et al. [20] | 1/21 (5%) | 0/7 (0%) | ||
| Madi et al. [19] | 1/20 (5%) | 1/6 (18%) | |||
| Kowalczyk et al. [21] | 0/40 (0%) | 5/32 (16%) | |||
| Total | 2/81 (2%) | 6/45 (13%) | |||
| Other | Schuetz et al. [20] | 3/21 (14%) | 1/7 (14%) | ||
| Madi et al. [19] | 0/20 (0%) | 0/6 (0%) | |||
| Kowalczyk et al. [21] | 0/40 (0%) | 0/32 (0%) | |||
| Total | 3/81 (4%) | 1/45 (2%) | |||
| Total | Schuetz et al. [20] | 0.12 | |||
| Madi et al. [19] | 0.56 | ||||
| Kowalczyk et al. [21] | 0.007 | ||||